Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Brain health
News from the Swiss Brain Health Plan (SBHP) 2023-2033
- Friedreich's ataxia
Treatment options have improved
- Focus on prevention
Colorectal cancer screening – an update
- Late-Breaking Science
Antithrombotics & rhythm
- Prostate cancer
Diagnosis without drama – ESMO 2025 under the banner of differentiated patient management
- Pneumococcal conjugate vaccine (PCV)
Best possible serotype coverage in the respective age group
- Psoriasis: intervening in the inflammatory cascade
Advantages of early biologic therapy and oral peptide as a beacon of hope
- AI-supported imaging and new biomarkers